Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Electroconvulsive Therapy01:30

Electroconvulsive Therapy

695
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
695
Depressive Disorders: Etiology01:27

Depressive Disorders: Etiology

383
Depressive disorders result from a complex interplay of biological, psychological, and sociocultural factors, each contributing uniquely to the development and persistence of the condition. Understanding these factors provides critical insight into the multifaceted nature of depression.
Biological Factors in Depression
Biological predispositions significantly influence the risk of developing depressive disorders. Genetic studies highlight the role of variations in the serotonin transporter...
383
Sedatives and Hypnotics Drugs: Miscellaneous Agents01:17

Sedatives and Hypnotics Drugs: Miscellaneous Agents

449
Sedatives and hypnotics encompass a wide range of substances, each with its unique mechanism of action, uses, and potential adverse effects.
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...
449
Depressive Disorders: MDD and Dysthymia01:27

Depressive Disorders: MDD and Dysthymia

505
Depressive disorders are a group of mental health conditions characterized by pervasive feelings of sadness, diminished pleasure in life, and a significant impact on daily functioning. These conditions are most prevalent in individuals during their 30s and affect women at twice the rate of men. Contrary to popular belief, younger individuals are generally more susceptible to these disorders than older adults. Two key types of depressive disorders include Major Depressive Disorder (MDD) and...
505
Depression: Overview01:18

Depression: Overview

699
Depression is a prevalent mental illness marked by persistent sadness and lack of interest in previously enjoyable activities. It can take several forms, including major depression, persistent depressive disorder, and bipolar I and II disorders. Symptoms range from emotional changes like chronic worry to physical changes like sleep disturbances and suicidal thoughts. From a neurobiological perspective, depression is believed to be triggered by abnormalities in the brain's prefrontal cortex,...
699

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regional, functional and transcriptomic decoding of multidimensional brain structure alterations in obsessive-compulsive disorder.

Nature communications·2026
Same author

Toward trustworthy clinical AI for obsessive-compulsive disorder: reliability, generalizability, and interpretability of a transformer model across the ENIGMA-OCD consortium.

medRxiv : the preprint server for health sciences·2026
Same author

Reward Circuit Adaptations After Chronic Antipsychotic Treatment Confer Addiction Vulnerability.

bioRxiv : the preprint server for biology·2026
Same author

Neural response to reward uncertainty in adolescents with mood and anxiety symptoms.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same author

Meta-analysis and meta-regression of diagnostic test accuracy of connectome-based predictive modeling in OCD.

Brain imaging and behavior·2026
Same author

KET-MCI: A Pilot Safety and Tolerability Study of Single Infusion Intravenous Ketamine for Older Adults with Depression and Mild Cognitive Impairment.

The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry·2026
Same journal

Cultural humility in the teaching and practice of clinical care.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same journal

Kappa opioid receptors mediate aversion-and it matters.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same journal

Splice isoforms of the histone variant macroH2A1 differentially regulate hippocampal gene expression and memory formation.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same journal

Chronic ethanol self-administration alters dopamine in the caudate nucleus and putamen of rhesus macaques in a sex-dependent manner.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same journal

In memoriam-Shigeto Yamawaki, M.D., Ph.D. (1954-2026).

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
Same journal

Top-down control of sustained attention by medial prefrontal cortex-locus coeruleus (mPFC-LC) projection neurons during the rodent continuous performance test (rCPT).

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology·2026
See all related articles

Related Experiment Video

Updated: Dec 31, 2025

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.0K

Ketamine normalizes subgenual cingulate cortex hyper-activity in depression.

Laurel S Morris1, Sara Costi1, Aaron Tan1

  • 1Depression and Anxiety Center for Discovery and Treatment, Department of Psychiatry, Icahn School of Medicine of Mount Sinai, New York, NY, USA.

Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology
|January 3, 2020
PubMed
Summary
This summary is machine-generated.

Ketamine rapidly treats major depressive disorder (MDD) by reducing overactive brain responses in the subgenual anterior cingulate cortex (sgACC) to positive stimuli. This study reveals a key neural mechanism for ketamine

More Related Videos

A Chronic Immobilization Stress Protocol for Inducing Depression-Like Behavior in Mice
05:28

A Chronic Immobilization Stress Protocol for Inducing Depression-Like Behavior in Mice

Published on: May 15, 2019

23.3K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.1K

Related Experiment Videos

Last Updated: Dec 31, 2025

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method
07:12

Individualized rTMS Treatment for Depression using an fMRI-Based Targeting Method

Published on: August 2, 2021

4.0K
A Chronic Immobilization Stress Protocol for Inducing Depression-Like Behavior in Mice
05:28

A Chronic Immobilization Stress Protocol for Inducing Depression-Like Behavior in Mice

Published on: May 15, 2019

23.3K
Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment
05:19

Author Spotlight: Therapeutic Benefit of Closed-Loop Deep Brain Stimulation in Depression Treatment

Published on: July 7, 2023

3.1K

Area of Science:

  • Neuroscience
  • Psychiatry
  • Pharmacology

Background:

  • Major depressive disorder (MDD) is linked to hyperactivity in the subgenual anterior cingulate cortex (sgACC).
  • The precise neural mechanisms underlying ketamine's rapid antidepressant effects are not fully understood.
  • Excessive glutamatergic input from the hippocampus to the sgACC may contribute to MDD pathophysiology.

Purpose of the Study:

  • To investigate if task-based sgACC activity is elevated in patients with MDD compared to healthy controls.
  • To determine if a single dose of ketamine alters task-based sgACC activity in MDD patients.
  • To explore the relationship between hippocampal-sgACC connectivity and sgACC reactivity.

Main Methods:

  • Two studies utilized functional magnetic resonance imaging (fMRI) with an incentive-processing task.
  • Study 1 compared task-based sgACC activity between MDD patients (N=28) and controls (N=20).
  • Study 2 examined changes in sgACC activity and connectivity before and after ketamine infusion (0.5 mg/kg) in MDD patients (N=14).

Main Results:

  • Patients with MDD exhibited higher sgACC activation to both positive and negative monetary incentives compared to controls.
  • MDD patients showed increased resting-state functional connectivity between the hippocampus and sgACC.
  • Ketamine administration significantly reduced sgACC hyper-reactivity to positive incentives, but not negative ones.

Conclusions:

  • Aberrant hyper-reactivity of the sgACC to positive incentives is a feature of MDD.
  • Ketamine's antidepressant action may stem from its ability to rapidly dampen this exaggerated sgACC response.
  • Findings suggest a specific neural pathway through which ketamine exerts its therapeutic effects in MDD.